Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sanofi ( (SNY) ) has provided an update.
In January 2025, Sanofi’s Consumer Healthcare business, Opella, announced a significant milestone as the FDA lifted the clinical hold on its actual use trial for Cialis, facilitating its potential switch from prescription to over-the-counter status. Additionally, Sanofi received EU approval for Sarclisa as the first anti-CD38 therapy combined with VRd for treating transplant-ineligible newly diagnosed multiple myeloma, marking a crucial advancement in their pharmaceutical offerings.
More about Sanofi
Sanofi is a global healthcare company focused on innovative solutions to improve lives, offering life-changing treatments and vaccines worldwide. The company emphasizes sustainability and social responsibility, with a presence on EURONEXT and NASDAQ markets.
YTD Price Performance: 7.86%
Average Trading Volume: 2,408,759
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $130.5B
See more data about SNY stock on TipRanks’ Stock Analysis page.
